Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations inBRCA1/2, mutations/deletions inPTENor PTEN loss, aberrations in otherBRCApathway genes, and germline mutations inBRCA1/2(not breast or ovarian cancer)